Form 4: Aquestive Therapeutics COO Stock Transaction

Aquestive Therapeutics COO Cassie Jung reported the withholding of 72,734 shares to satisfy tax obligations upon the vesting of performance stock units.

Summary

• Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, Inc., executed a transaction on May 5, 2026.
• The transaction involved the withholding of 72,734 shares of common stock by the company.
• The withholding was conducted to satisfy tax obligations related to the vesting of previously granted Performance Stock Units (PSUs).
• The shares were withheld at a price of $4.18 per share.
• Following this transaction, the reporting person maintains direct beneficial ownership of 202,246 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard tax-related transaction rather than a discretionary sale of stock.

Positives

• The transaction reflects the vesting of performance-based equity, indicating the achievement of specific corporate or individual performance milestones.

Negatives

• The transaction resulted in a reduction of the reporting person's direct shareholding in the company.

Risks

• None identified in this specific filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a routine administrative filing related to executive compensation and tax compliance, which is standard practice for publicly traded pharmaceutical companies.

Comparison to Industry Standards

• The use of 'sell-to-cover' transactions to satisfy tax obligations upon equity vesting is a standard industry practice for executive compensation in the biotech sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related equity settlement.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Form 4, Insider Trading, Equity Vesting, Chief Operating Officer